Regulatory News : <\/p>\n
A major player in the field of in vitro diagnostics and world leader in industrial microbiology, bioMrieux (Paris:BIM) has announced the appointment of Nicolas Cartier as Corporate Vice President, Industrial Microbiology Unit, effective starting today. <\/p>\n
Before joining bioMrieux, Nicolas Cartier, spent most of his professional career at Sanofi. Since 2009, he has been General Manager of Sanofi France, the Groups second largest affiliate. Prior to that, he gained 10 years international experience through various roles in particular in Thailand, where he was in charge of commercial development for the Southeast Asia region within the Animal Health Division, in Shanghai, where he headed up Sanofi Chinas Pharmaceutical Division and in Mexico City, where he was General Manager of Sanofi Mexico. In France, Nicolas Cartier was Chief of Staff in the office of the Chairman and CEO of Sanofi France and then Business Unit Manager. <\/p>\n
Nicolas Cartier will be a member of bioMrieuxs Management Committee, reporting directly to Jean-Luc Belingard, Chairman and CEO of bioMrieux. <\/p>\n
\"I am delighted to welcome Nicolas Cartier, said Jean-Luc Belingard. \"He will successfully pilot our ambitious strategy in industrial microbiology, one of our most promising fields of specialization. His international experience and his knowledge of the pharmaceutical sector will represent valuable assets, enabling bioMrieux to meet the current challenges our customers have to face in industry in order to guarantee the safety and quality of their agri-food, pharmaceutical and cosmetic products worldwide. <\/p>\n
With over 20 years expertise in industrial microbiological control, bioMrieux provides diagnostic solutions for customers in the agri-food, pharmaceutical and cosmetic industries. In 2012, the Company launched a new veterinary diagnostics activity with the aim of developing solutions to combat animal diseases and zoonoses while contributing to the prudent use of antibiotics in veterinary medicine. Today, bioMrieux offers the largest microbiological control product range on the market, and industrial applications account for more than 20% of the Groups business. Over 200 employees* contribute to building the success of the Industrial Microbiology Unit, which combines research and marketing activities to ensure the competitiveness of our commercial offering and support the development of the laboratories we serve. <\/p>\n
* full-time equivalent <\/p>\n
About the Industrial Microbiology Unit: <\/p>\n
bioMrieux offers the broadest range of solutions for industrial microbiological control with both manual and automated methods to provide rapid, reliable results for the agri-food, biopharmaceutical and cosmetic industries. This range provides solutions to cover every step of microbiological analysis, from sample preparation through to final microorganism identification. <\/p>\n
About bioMrieux <\/p>\n
<\/p>\n
Originally posted here: Regulatory News : A major player in the field of in vitro diagnostics and world leader in industrial microbiology, bioMrieux (Paris:BIM) has announced the appointment of Nicolas Cartier as Corporate Vice President, Industrial Microbiology Unit, effective starting today. Before joining bioMrieux, Nicolas Cartier, spent most of his professional career at Sanofi. Since 2009, he has been General Manager of Sanofi France, the Groups second largest affiliate. Continue reading
\nNicolas Cartier Appointed Corporate Vice President, Industrial Microbiology Unit of bioM\u00e9rieux<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"